Nasir Ayesha, Yasmin Haleema, Korejo Razia
Department of Obstetrics and Gynaecology, Jinnah Postgraduate Medical Centre, Karachi.
J Pak Med Assoc. 2011 Oct;61(10):998-1001.
To determine the efficacy and safety of subcutaneously administered recombinant human erythropoietin in combination with intravenous iron sucrose for the management of iron deficiency anaemia in gynaecological patients in Jinnah Postgraduate Medical Centre Karachi.
It was an interventional quasi experimental study carried out in the Department of Obstetrics /Gynaecology, at JPMC from 1st Nov 2007 to May 2008. All patients with indications for major Gynaecological surgery with iron deficiency anaemia having a mean haemoglobin level of 7 gm/dl were selected and the target haemoglobin was 11 gm/dl. Patients who were symptomatic, had chronic bleeding, renal failure or had signs of anaemia other than iron deficiency were excluded from the study. All investigations were done on day one before the start of therapy, and then treatment was initiated with recombinant human erythropoietin in a dose of 5000 IU subcutaneously and injection Iron Sucrose 200 mg in 100cc NaCI intravenously on 3 alternate days. The parameters checked in succession on day 4 and day 10 included increase in haemoglobin level, haematocrit, reticulocyte count, and time required to reach the target haemoglobin.
Twenty three patients fulfilled the inclusion criteria and were selected for the study. At the end of 10 days of starting therapy increase in haemoglobin was on an average of 2.8 gm/dl, increase in mean corpuscular volume was 4fl, Serum Iron increased by 99.86 ug%, total iron binding capacity decreased by 30.86%, transferrin saturation increased by 15.5% .There were no serious reactions to Erythropoietin or Iron sucrose
It is concluded that recombinant erythropoietin along with iron sucrose safely increased the haemoglobin level in 10 days to the target level thus rendering the patients fit for surgery and, none of the selected patients needed blood transfusion.
确定在卡拉奇真纳研究生医学中心,皮下注射重组人促红细胞生成素联合静脉注射蔗糖铁治疗妇科缺铁性贫血的疗效和安全性。
这是一项于2007年11月1日至2008年5月在真纳研究生医学中心妇产科进行的干预性准实验研究。选取所有因妇科大手术有缺铁性贫血指征且平均血红蛋白水平为7克/分升的患者,目标血红蛋白为11克/分升。有症状、慢性出血、肾衰竭或有除缺铁性贫血以外贫血体征的患者被排除在研究之外。所有检查均在治疗开始前的第一天进行,然后开始治疗,皮下注射剂量为5000国际单位的重组人促红细胞生成素,并每隔一天静脉注射100毫升氯化钠中含200毫克的蔗糖铁注射液。在第4天和第10天依次检查的参数包括血红蛋白水平的升高、血细胞比容、网织红细胞计数以及达到目标血红蛋白所需的时间。
23名患者符合纳入标准并被选入研究。开始治疗10天后,血红蛋白平均升高2.8克/分升,平均红细胞体积增加4飞升,血清铁增加99.86微克%,总铁结合力降低30.86%,转铁蛋白饱和度增加15.5%。对促红细胞生成素或蔗糖铁均无严重反应。
得出结论,重组促红细胞生成素与蔗糖铁一起可在10天内安全地将血红蛋白水平提高到目标水平,从而使患者适合手术,且所选患者均无需输血。